PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 562 (xsd:integer)
nif:isString
  • Vemurafenib-related severe AEs with early onset are reported in patients who were previously treated with anti-PD-1 (anti-programmed cell death-1) antibodies, especially in the preceding 4 weeks.8 9 According to preliminary evidence, the combination of BRAF/MEK-inhibitors with anti-PD-1 antibodies results in a significantly higher toxicity profile compared with current treatment protocols, with more than half of patients experiencing a grade 3-5 AE and 40% discontinuing at least one of the drugs in phase II of their ongoing clinical trial KEYNOTE-022 [10].
rdf:type